rip-wire.com
Picamilon

This Russian Drug Picamilon Rapidly Penetrates The Blood-Brain Barrier, Producing A Beneficial Effect on The Brain's Metabolism
by A.L. Karayev

The chemical modification of widely used vitamins is one of the fundamental trends in the search for new pharmaceutical agents. The main advantages of vitamin-like drugs are the broad spectrums of action, the easy penetration through cellular membranes, the low toxicity, and the rare side effects. The broad spectrum of action of these agents is connected not only with their influence on unspecific metabolic processes, but also on various neurotransmitter systems.

In experiments, Picamilon decreases cerebral blood-vessel tone and increases intracranial circulation rate. The drug exceeds in force and duration the effects of GABA and niacin alone. In small doses, Picamilon shows tranquilizing action to prevent the negative effects of emotional stress. As with diazepam, it depresses motivative aggression. The tranquilizing influence of the drug on negative emotions expressed through the hypothalamic system has been proved. Picamilon is characterized by a tranquilizing effect, without a sedative component but with elements of stimulant action.

The drug effectively counteracts stress and lowers the depressing influence of ethanol on the behavior of animals. It rapidly penetrates through the blood-brain barrier and improves the functional state of the brain by producing a beneficial effect on its metabolism.

Picamilon has been found to have low toxicity during experiments on animals. The median lethal dose is more than 10 gram per kilogram of body weight and more than 6 g/kg intravenously. The low toxicity was demonstrated during six months of chronic toxicity testing when the drug displayed no allergenic, carcinogenic, teratogenic or embryotoxic action.

Independent researchers in 16 medical centers in Russia carried out a clinical trial with Picamilon in a great number of patients. Picamilon was prescribed two or three times a day in doses of 20 to 50 mg. The course of therapy ranged from two weeks to three months.


Significant Neurologic Improvement

Picamilon proved to be quite effective in patients with acute brain syndrome. On the second or third day after taking the medicine, the patients showed significant neurologic improvement. The positive dynamics of the cerebral signs were noted. The effect increased when taking the drug, especially during the second and third week of treatment. In this case, objective methods of examination were used to document the increase of cerebral circulation, and the normalization of cerebrovascular resistance.

Picamilon was effective in patients with mild-to-moderate impairment during subacute and early convalescent periods. It improved emotional conditions, speech and memory. Patients showed increased general activity, and better work and social adaptation.

Picamilon stimulated physical and psychic rehabilitation from various asthenic (weakening) disorders due to mental and somatic pathology. Picamilon was effective in patients with neurotic disorders in which the leading signs were asthenic-asthenodepression, and asthenohypochondriac disturbances that accompany fear, anxiety, fatigue, emotional and vegetative instability, and sleep disturbances.

Picamilon reduced anxiety and hyperesthesia (whereby normal touch creates pain) without sedative effects, which improved sleep. According to the majority of researchers, usage of Picamilon employed as a means of correcting neuroses, manic-depressive syndrome, involutional depression and schizophrenia enabled doctors to decrease doses of psychotropic drugs used in the treatment of these conditions. The combining of Picamilon with conventional treatments accelerated reduction of the psychopathological signs when compared to conventional treatments alone.


Improvement in A Week

Picamilon also was effective in patients with psycho-organic syndromes including cerebral atherosclerosis, brain injury from physical trauma, and toxic lesions of the brain. The condition of these patients took a turn for the better by the end of the first week.

The effectiveness of Picamilon in patients with migraine headache was studied. It has been established that the drug has a pronounced effect on painful hemicrania-pain or headache in one side of the head-by decreasing its intensity and mitigating or stopping any accompanying symptoms. In persons suffering from chronic alcoholism, Picamilon alleviated withdrawal symptoms.


Alcohol Withdrawal Aided

The effectiveness of Picamilon was compared with other similar drugs, including piracetam, phenazepam, diazepam, vinpocetine, xanthinol nicotinate, and papaverin. It was noted that the psycho-stimulant effect of Picamilon was greater than piracetam. After taking Picamilon the patients felt significantly better. Giddiness and tremor disappeared quicker.

Most patients preferred Picamilon to piracetam. It normalized the behavior of patients faster and more completely than piracetam. In another study, Picamilon acted faster than vinpocetine in treating withdrawal symptoms in patients suffering from chronic alcoholism.

According to clinical studies, Picamilon is recommended for the treatment of cerebrovascular diseases in subacute and early convalescent periods, as well as for transient brain damage, neurocirculatory dystonia, and chronic cerebral circulatory insufficiency. The drug is recommended as a tranquilizer possessing no sedative action. Picamilon can be prescribed in cases of asthenic (weakening) syndrome and disorders due to various psychotic and somatic pathology. It is used in the treatment of depressive disorders in the elderly and as therapy for senile psychoses. It also is recommended for the prevention and treatment of anxiety and stress. In persons suffering from chronic alcoholism, Picamilon may be used to relieve the symptoms of withdrawal.
Order Now!

How And Why Picamilon Works

Studies from Russia demonstrate that Picamilon improves nervous control, recovery time after work, blood pressure and memory. The drug even shows benefits in treating brain trauma.
By R. P. Kruglikova

Drugs that normalize the gamma aminobutyric acid (GABA) system consist mainly of substances that activate GABA receptors, inhibit GABA utilization or increase the permeability of the blood-brain barrier to GABA. One way of creating preparations of this kind is to use substances that are carriers of the GABA molecule, including vitamins or their derivatives and, in particular, nicotinic acid (niacin).

Niacin has been chosen as the carrier because of its valuable pharmacological properties, its low toxicity, and its high biological availability. It has therefore been suggested that a combination of niacin and GABA in the same molecule would increase the potency of each component.

Picamilon (nicotinyl-y-aminobutyric acid) was first synthesized at the All-Union Vitamin Research Institute in 1970. It is a white crystalline powder that is odorless, highly hygroscopic (takes up moisture readily), and readily soluble in water.

In studies in animals Picamilon has been shown to have positive action on the cerebral circulation, and also exhibits the properties of a tranquilizer with a stimulating component. Unlike tranquilizer drugs, Picamilon does not induce muscle relaxation, drowsiness or lethargy.

The action of the compound on cerebral circulation and on neural regulation was studied in anesthetized cats; conscious, unrestrained cats; and on unanesthetized rabbits. Picamilon stimulated cerebral circulation and lowered vascular tone in both arterial systems of the brain. The increase in the blood supply to the brain in conscious animals took place to a more marked degree than in cats under general anesthesia. The drug also lowered blood pressure. It must be emphasized that these effects manifested themselves after both intravenous and oral administration of the compound. In all the animals, Picamilon increased blood flow.

In the strength and duration of its cerebrovascular effect, Picamilon is much superior both to GABA and to niacin. Under the same experimental conditions, GABA in a dose of 10 mg/kg (intravenously) caused no change in cerebral blood flow, and only when given in a dose of 300 mg/kg did it increase blood flow, with the effect lasting three to five minutes. Niacin in large doses (50 to 100 mg/kg) increased cerebral blood flow by 5 to 10 percent.


Brain Blood Flow

In its effect on cerebral circulation, Picamilon was shown to be more effective than papaverine, nialamide, complamin (xantinol nicotinate), and dihydroergotoxin (redergin).

An essential role in the mechanism of action of Picamilon is its effect on nervous control of the cerebral circulation. It weakens changes in cerebral blood flow during the vasomotor reflex, considerably inhibits constrictor responses of vessels in the carotid and vertebrobasilar basins due to stimulation of afferent fibers of somatic nerves, and causes gradually developing inhibition of tonic and reflex activity in sympathetic nerves.

Neuropharmacological screening tests on Picamilon have demonstrated its tranquilizing properties in small doses. For instance, at a dose of l mg/kg, Picamilon prevents the negative consequences of emotional stress (in cats it normalizes the orienting reaction when disturbed by the response to rage and fear). Like diazepam, it has an inhibitory effect on motivated aggression, associated with fighting for territory in rats.

Investigation of Picamilon's effect on the threshold of "self-stimulation" showed that in higher doses (80 and 160 mg/kg), in contrast with small doses which have a tranquilizing effect, Picamilon lowered the "self-stimulation" threshold (like amphetamine), but at the same time reduced the number of self-stimulation. The stimulating action of the drug also has been shown in general anesthesia. For instance, at a dose of 100 mg/kg, Picamilon reduced by 1.7 times the duration of the sedative effect of hexobarbital sodium and reduced by half the duration of thiopental anesthesia.

Unlike tranquilizer drugs (chlorodiazepoxide, diazepam, relanium, phenazepam), Picamilon does not induce muscle relaxation, drowsiness or lethargy. Clinicians have stated that the drug closely resembles cavinton (the ethyl ester of apovincamic acid), but comparison of the properties of the two compounds showed that Picamilon is superior.

After the administration of Picamilon at a dose of 5 mg/kg, defense-conditioned reflexes (jumping onto a rod) were restored after their disappearance due to fatigue (by 130 percent, compared with 12 percent in the control). Given to rats at a dose of 50 mg/kg it restored physical working capacity during a rest period of one hour by 76 percent, compared with 38 percent in the controls.

In a model of shock-induced amnesia of the conditioned passive avoidance reaction, like other GABA-ergic drugs (sodium hydroxy butyrate, fenibut, pantogam), Picamilon exhibited anti-amnesiac properties. In hypoxic states, the compound was found to have antihypoxic activity. The presence of anti-amnesiac and antihypoxic properties in the spectrum of action of Picamilon places it in the group of nootropic agents.

There is evidence that activation of the GABA-ergic system in various kinds of stress can prevent damage to the body when exposed to various stimuli. In confirmation of this hypothesis, scientists who studied the effect of GABA derivatives on the development of toxic (nicotinic) cerebral edema (fluid on the brain), showed that Picamilon in a dose of 500 mg/kg, injected 30 minutes before nicotine (40 mcg/kg), prevented the development of edema. If the compound was given at a dose of 200 to 300 mg/kg, the density of the brain tissue was increased, but not up to the control level, and the total water content had no significant change. They suggested that the mechanism of the anti-edematous action of Picamilon is linked with a change in energy metabolism in neurologic tissue. Quickly through The Blood Barrier

Thirty minutes after injections of Picamilon into rats at a dose of 100 mg/kg (intraperitoneally) the concentration of the oxidized form of nicotinamide adenine dinucleotide (NAD) in the brain rises by 67 percent above the control level, and that serum lactate dehydrogenase activity falls by 23 percent, with glutamateoxalate transaminase activity showing no significant change. A more prolonged action of the compound led to normalization of the NAD level in the rats' brains.

The study of the effect of Picamilon on active GABA uptake by synaptosomes in the rat cerebral cortex showed that it moderately inhibits GABA uptake by synaptosomes, whereas niacin has no appreciable inhibitory action on this process.

Scientists at the Department of Biochemistry, Odessa University, found that Picamilon passes quickly through the blood-brain barrier. As early as 30 minutes after subcutaneous injection, the compound was found in the brain, penetrating it by an order of magnitude more rapidly than GABA. The time course of accumulation of Picamilon in the brain correlated with its blood level. Accumulation of the compound in muscle tissue one to two hours after injection was greater (10 times) than that of GABA. Picamilon is retained in the body longer than GABA.

A six-month toxicity study showed that Picamilon does not change the behavior or condition of rats when administered in doses of three to 75 mg/kg, and causes no significant changes in the blood, urine and internal organs of the animals. Some morphological changes were found in the kidneys of rats receiving Picamilon in a dose of 75 mg/kg (15 times higher than the therapeutic dose). A microscopic study of the kidneys indicated manifestations of glomerulonephritis and nephrosclerosis, which led to the consideration of renal pathology as a contraindication to Picamilon. However, during clinical studies with Picamilon- even when administered over a long period or in repeated courses-no disturbances were found in the kidneys or the urinary system.
Order Now!
Adverse Effects Few

Picamilon produces no allergenic, teratogenic, embryotoxic or carcinogenic effects. On this basis, the pharmacological committee of the Ministry of the Health (Russia) recommended clinical trials of Picamilon for cerebrovascular disturbances, as a daytime tranquilizer, as a stimulant in depressive and asthenic (weakening) states, and to improve physical and mental working capacity. Picamilon was studied in a large number of scientific facilities within Russia. The total number of patients under observation was 984. Picamilon tablets were prescribed two to three times a day at a dose of 0.02 to 0.05 grams, and in a daily dose of 0.04 to 0.3 grams. Courses of treatment lasted from two weeks to one-and-a-half months. The effectiveness of treatment was assessed by clinical and laboratory tests. Cerebral blood movements were evaluated by objective methods, including echopulsography, echoencephalography, rheo- encephalography, ultrasonic scanning, biomicroscopy of the conjuctiva, and electroencephalography.

In patients with acute cerebrovascular disturbances, improvement occurred on the fourth or fifth day, when the severity of neurologic symptoms was reduced. Later, headache, dizziness, noise in the head and memory disorders were reduced, motor and speech disorders began to regress rapidly, sleep improved, and irritability, emotional stress and anxiety were reduced. The velocity of cerebral blood flow was increased.

Administration of Picamilon to patients suffering from the results of cerebrovascular disturbances (more than a month later) proved effective after the second or third day of treatment. The patients' emotional background, speech and memory were improved, and levels of enzyme activity (AST, ALT, LDH) and lactate concentration were restored to normal.

Scientists who studied the effects of GABA derivatives on the development of toxic cerebral edema (fluid on the brain) showed that Picamilon in specific doses prevented the development of edema.

In chronic cerebral insufficiency, Picamilon improved the mood and memory of the patients, reduced irritability and tearfulness, abolished autonomic vascular manifestations, and reduced metabolic disturbances. In patients with memory disorders (global amnesia), considerable improvement in memorization and recall was observed on the fifth to seventh day of treatment, and the patients were able to return to work.

In patients with astheno-neurotic anxiety and depression, activation of mental functions and motor activity was observed, including improved speed and quality of operative activity, concentration of attention and mood, relief of anxiety, improved working capacity, and so on. The use of Picamilon in depression, along with moderate doses of tricyclic antidepressants, enabled the doses of the latter to be reduced. In patients with alcoholism, Picamilon abolished many withdrawal symptoms, especially apathy, weariness and lethargy. The patients later become more tranquil, less fussy and anxious, and their working capacity improved.


Lowers Blood Pressure

The effect of Picamilon on cerebral blood flow was compared with that of papaverine and complamin. The scientists found that Picamilon had a stronger blood pressure-lowering effect than papaverine; complamin mainly affects the peripheral circulation, and it exhibits neither tranquilizing nor stimulating properties.

Picamilon is an approved drug in Russia. It is intended for use in adults as a vasoactive (effecting the caliber of blood vessels) and nootropic (benefiting cognition and nerves) agent for acute cerebrovascular disturbances of mild severity, chronic cerebrovascular insufficiency, and vegetovascular dystonia (an imbalance between sympathetic and parasympathetic influences on vascular tone). The drug is indicated as a tranquilizer for states of anxiety, fear, increased irritability and emotional stress. Picamilon is recommended for depressive disorders in the elderly and for senile psychoses. In management of drug addictions, the compound can be used to abolish withdrawal symptoms in chronic alcoholics. Picamilon is supplied in 0.01, 0.02, and 0.05 gram tablets. It has a useful shelf life of three years.
Order Now!
Testimonials
"Hard to believe the results I've gotten so far. In the first 10 days I've lost 6 1/2 lbs of this ugly fat. Looking forward to the next 10 days and beyond."
- Lorena Smiley
"The hardest part for me when i dieted in the past was my almost uncontrollable hunger pangs. I almost forgot to eat the instant i started taking Ripwire. I've already lost about 2 inches off my waist and it's only been 2 weeks!."
- Melinda Ripson
"Wow, my thinking ability has shot through the roof! I'm recalling things I had trouble remembering before. Oh, and have also lost 8 lbs in the last 9 days. Thanks for a great product!."
- Richard Masteron
"I lost 24 lbs in 30 days. I don't think I need to say any more, do I? Thanks for a great product. You're not going to run out of this stuff any time soon, are you?."
- Johnny Lestonir
100% Guaranteed
Ripwire is so effective it is backed by the most generous guarantee found in the entire supplement world. A 1-year, no questions asked, money-back guarantee as follows:
365 Day Money Back Guaranteed
Order Now!
If you are not completely satisfied by RIPWIRE for any reason, please return every bottle you have purchased during the past year for a full, and complete, gracious refund. There is no fine print, or special qualifications. If RIPWIRE doesn’t do for you what we say it will, then please take us up on our friendly guarantee and return it any time within 1 year of purchase.